NEW YORK (GenomeWeb) — UK diagnostics firm RenalytixAI said on Thursday that it raised roughly $29 million earlier in the month to support the launch of its kidney disease test KidneyIntelX next year.

In early November, Renalytix announced it had floated its shares on the London Stock Exchange after raising approximately £22.3 million ($28.7 million) through a stock placement, US subscription, and restricted offer to shareholders of its parent firm, EKF Diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.